A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

• Published in: BMC medicine Vol. 20; no. 1; p. 472
• Main Authors: Li, Ning, Wu, Tao, Hong, Yong-Gui, Guo, Yan-Zhen, Cheng, Yu-Feng, Ma, Yi-Jie, Bie, Liang-Yu, Cui, Dong-Hai, Gao, Xiao-Hui, Tan, Bing-Xu, Li, Bao-Sheng, Luo, Su-Xia, Wang, Jun-Sheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.12.2022; BioMed Central; BMC
• Subjects: Advanced esophageal squamous cell carcinoma; Angiogenesis; Anlotinib; Anticancer properties; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antitumor agents; Biomarkers; Bone marrow; c-Kit protein; Cancer; Cancer therapies; Chemotherapy; China; Cisplatin; Cisplatin - therapeutic use; Clinical medicine; Clinical trials; Disease control; Dosage and administration; Drug therapy; Drug therapy, Combination; Effectiveness; Efficacy; Esophageal cancer; Esophageal Neoplasms - drug therapy; Esophageal Squamous Cell Carcinoma - drug therapy; Ethics; Growth factors; Health services; Humans; Intravenous administration; Kinases; Medical prognosis; Metastases; Metastasis; Myelosuppression; Neutropenia; Paclitaxel; Paclitaxel - therapeutic use; Patients; Protein-tyrosine kinase; Relapse; Safety; Safety management; Squamous cell carcinoma; Subgroups; Survival; Testing; Therapy; Toxicity; Tumors; Tyrosine; Vomiting; China; Anlotinib; First-line therapy; Paclitaxel; Efficacy; Safety; Cisplatin; Advanced esophageal squamous cell carcinoma

Anlotinib, a tyrosine kinase inhibitor, has shown encouraging anti-tumor activity in esophageal squamous cell carcinoma (ESCC). This study was designed to assess the efficacy and safety of anlotinib plus paclitaxel and cisplatin (TP) as first-line therapy for advanced ESCC. In a multi-center, single...